Amplification of MET gene in anti-EGFR resistant colorectal cancer

被引：0
|
作者：
Bond, Theo
机构：
来源：
PHARMACOGENOMICS | 2013年 / 14卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：1249 / 1249
页数：1
相关论文
共 50 条
  • [31] The oligoclonal anti-EGFR antibody MM-151 synergizes with trametinib in KRAS wildtype and mutant colorectal cancer models resistant to conventional monoclonal anti-EGFR antibodies
    Landenranta, J.
    Gerami-Moayed, N.
    Burenkova, O.
    Masson, K.
    Raue, A.
    Wainszelbaum, M.
    MacBeath, G.
    EUROPEAN JOURNAL OF CANCER, 2016, 69 : S131 - S131
  • [32] Retreatment with anti-EGFR based therapies in metastatic colorectal cancer: impact of intervening time interval and prior anti-EGFR response
    Liu, X.
    George, G. C.
    Tsimberidou, A. M.
    Naing, A.
    Wheler, J. J.
    Kopetz, S.
    Fu, S.
    Piha-Paul, S. A.
    Eng, C.
    Falchook, G. S.
    Janku, F.
    Garrett, C.
    Karp, D.
    Kurzrock, R.
    Zinner, R.
    Raghav, K.
    Subbiah, V.
    Hess, K.
    Meric-Bernstam, F.
    Hong, D. S.
    Overman, M. J.
    BMC CANCER, 2015, 15
  • [33] Reply: EGFR alterations and response to anti-EGFR therapy: is it a matter of gene amplification or gene copy number gain?
    A Ålgars
    M Lintunen
    O Carpén
    R Ristamäki
    J Sundström
    British Journal of Cancer, 2012, 106 : 428 - 428
  • [34] Retreatment with anti-EGFR based therapies in metastatic colorectal cancer: impact of intervening time interval and prior anti-EGFR response
    X. Liu
    G. C. George
    A. M. Tsimberidou
    A. Naing
    J. J. Wheler
    S. Kopetz
    S. Fu
    S. A. Piha-Paul
    C. Eng
    G. S. Falchook
    F. Janku
    C. Garrett
    D. Karp
    R. Kurzrock
    R. Zinner
    K. Raghav
    V. Subbiah
    K. Hess
    F. Meric-Bernstam
    D. S. Hong
    M. J. Overman
    BMC Cancer, 15
  • [35] Reply: EGFR alterations and response to anti-EGFR therapy: is it a matter of gene amplification or gene copy number gain?
    Algars, A.
    Lintunen, M.
    Carpen, O.
    Ristamaki, R.
    Sundstrom, J.
    BRITISH JOURNAL OF CANCER, 2012, 106 (02) : 428 - 428
  • [36] EGFR Downregulation after Anti-EGFR Therapy Predicts the Antitumor Effect in Colorectal Cancer
    Okada, Yasuyuki
    Kimura, Tetsuo
    Nakagawa, Tadahiko
    Okamoto, Koichi
    Fukuya, Akira
    Goji, Takahiro
    Fujimoto, Shota
    Sogabe, Masahiro
    Miyamoto, Hiroshi
    Muguruma, Naoki
    Tsuji, Yasushi
    Okahisa, Toshiya
    Takayama, Tetsuji
    MOLECULAR CANCER RESEARCH, 2017, 15 (10) : 1445 - 1454
  • [37] Association between EGFR gene polymorphisms, skin rash and response to anti-EGFR therapy in metastatic colorectal cancer patients
    Jaka, Ane
    Gutierrez-Rivera, Araika
    Ormaechea, Nerea
    Blanco, Jesus
    La Casta, Adelaida
    Sarasqueta, Cristina
    Izeta, Ander
    Tuneu, Anna
    EXPERIMENTAL DERMATOLOGY, 2014, 23 (10) : 751 - 753
  • [38] Consensus recommendations for the use of anti-EGFR therapies in metastatic colorectal cancer
    Cripps, C.
    Gill, S.
    Ahmed, S.
    Colwell, B.
    Dowden, S.
    Kennecke, H.
    Maroun, J.
    Samson, B.
    Thirlwell, M.
    Wong, R.
    CURRENT ONCOLOGY, 2010, 17 (06) : 272 - 278
  • [39] Overexpression of MET is a new predictive marker for anti-EGFR therapy in metastatic colorectal cancer with wild-type KRAS
    Tomokazu Kishiki
    Hiroaki Ohnishi
    Tadahiko Masaki
    Kouki Ohtsuka
    Yasuo Ohkura
    Jyunji Furuse
    Takashi Watanabe
    Masanori Sugiyama
    Cancer Chemotherapy and Pharmacology, 2014, 73 : 749 - 757
  • [40] Overexpression of MET is a new predictive marker for anti-EGFR therapy in metastatic colorectal cancer with wild-type KRAS
    Kishiki, Tomokazu
    Ohnishi, Hiroaki
    Masaki, Tadahiko
    Ohtsuka, Kouki
    Ohkura, Yasuo
    Furuse, Jyunji
    Watanabe, Takashi
    Sugiyama, Masanori
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 73 (04) : 749 - 757
12345